论文部分内容阅读
目的通过As2O3联合格列卫对Bac/Abl的作用靶点及二者药物作用无交叉耐药性的机制,达到使两种药发挥协同作用,更有效地治疗难治性慢性粒细胞白血病的目的.方法使用格列卫200~400 mg/d,加As2O310 mg/次,7~10 d/月作为一个周期,共用2~3个周期以评价疗效.结果9例均为单用格列卫无效的患者,经联合使用后有3例达到血液学缓解,3例达到部分缓解,3例未缓解或恶化;9例均未达到细胞遗传学及分子生物学的缓解.结论对格列卫耐药的难治性慢性粒细胞白血病患者,继续联合应用As2O3,可以使部分患者达到缓解或部分缓解,二者无交叉耐药性并具有良好的协同作用.
OBJECTIVE: To aim at the combination of two drugs with synergistic effect and effective treatment of refractory chronic myeloid leukemia by arsenic trioxide combined with Gleevec on the target of Bac / Abl and the mechanism of drug resistance between the two drugs .Methods The use of Gleevec 200 ~ 400 mg / d, plus As2O3 10 mg / time, 7 ~ 10 d / month as a cycle, sharing 2 to 3 cycles to evaluate the efficacy.Results 9 cases were single with Gleevec invalid Of patients, 3 cases achieved hematological remission, 3 cases achieved partial remission, 3 cases did not alleviate or worsen after combination.All 9 cases did not reach the cytogenetics and molecular biology remission.Conclusion: Of patients with refractory chronic myeloid leukemia, continue to use As2O3, can make some patients achieve remission or partial remission, both without cross-resistance and have a good synergy.